Article
EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan.
Cancer letters - 28 Aug 2026
Harmych Sarah J, Joshi Neeraj, Tanaka Hidenori, Bogatcheva Galina, Ramirez Marisol A, Graves-Deal Ramona, Tydings Claiborne W, Elia Marina T, Mueller Hunter R Lischwe, Silvestri Isabella M, Ti Ning Khaw, Wahoski Claudia C, Sievers Chelsie K, Higginbotham James N, Irudayam Maria Johnson, Revetta Frank L, Zhao Zhiguo, Franklin Jeffrey L, Yilma Binyam, O'Grady Tina M, Fragkogianni Stamatina, Ciampricotti Metamia, Washington M Kay, Guo Xingyi, Lovly Christine M, Walker Allison S, Meiler Jens, Mudumbi Krishna C, Liu Qi, Coffey Robert J, Rosenthal Eben, Singh Bhuminder
Abstract excerpt
Epidermal growth factor receptor (EGFR) is an oncogenic driver in multiple cancers and a therapeutic target of tyrosine kinase inhibitors and neutralizing monoclonal antibodies. However, resistance to EGFR-targeted therapies, particularly the anti-EGFR antibody cetuximab, remains a clinical challenge in colorectal (CRC) and head and neck (HNSCC) cancers. Cetuximab exerts its antitumor activity by blocking...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.